FindTrial
Sign In

Screening of biomarkers for the patients with hepatic sinusoidal obstruction syndrome induced by pyrrolidine alkaloid

Screening of biomarkers for the patients with hepatic sinusoidal obstruction syndrome induced by pyrrolidine alkaloid

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-SDD-16009119
Enrollment
Unknown
Registered
2016-08-30
Start date
2016-08-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic sinusoidal obstruction syndrome

Interventions

Case series:Nil

Sponsors

Division of Gastroenterology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged more than 18 years old; 2. willing to participate the projext; 3. a history of taking gynura segetum; 4. For HSOS, the patients satisfied the Seattle criteria. Two of three findings must occur within 20 days of transplantation: billirubin>2 mg/dL (1mg/dl =17.1umol/L), hepatomegaly or right upper quadrant pain, ascites or greater than 2% weight gain due to fluid accumulation.

Exclusion criteria

Exclusion criteria: 1. history of chronic liver diseases; 2. use of drug which result in the liver injury; 3. concurred with liver cancer, Budd-chiari synrome, congestive heart failure; 4. pragnant,mental disease.

Design outcomes

Primary

MeasureTime frame
liver function;Computed Tomography;Magnetic Resonance Imaging;—

Countries

China

Contacts

Public ContactYuhu Song

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

yuhusong@163.com+86 15007187581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026